Editorial comments on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'.
Bunn
P A
PA
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000890:Anti-Infective Agents; D019072:Antibiotic Prophylaxis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002939:Ciprofloxacin; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D023381:Endpoint Determination; D005047:Etoposide / Q000008:administration & dosage; D005334:Fever / Q000139:chemically induced* / Q000517:prevention & control*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced* / Q000517:prevention & control*; D010166:Palliative Care; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D015575:Roxithromycin / Q000008:administration & dosage / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D016179:Granulocyte Colony-Stimulating Factor; D015575:Roxithromycin; D002939:Ciprofloxacin; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide